Skip to main content

Table 2 Analysis of the influencing factors of pregnancy, neonatal complications and child death

From: Use of trastuzumab in treating breast cancer during pregnancy: a systematic review and meta-analysis

Characteristic

 

Pregnancy/fetal

95%CI

P

New born complication

95%CI

P

Child deaths

95%CI

P

Yes

No

OR

Yes

No

OR

Yes

No

OR

Age (years)

 > 30

10

3

0.95

0.125–7.275

1

10

3

7.78

1.2–50.424

0.04

3

7

3

0.248–36.325

0.588

 ≤ 30

7

2

3

7

1

7

Tumor stage

IV

10

2

3.33

0.319–34.830

0.538

7

5

2.1

0.251–17.594

0.62

2

9

NA

NA

1

I–III

3

2

2

3

0

4

Exposed gestational stage

1st trim

0

2

NA

NA

0.043

0

2

NA

NA

0.178

0

2

NA

NA

1

others

17

3

13

8

2

14

Trastuzumab schedule

3 weeks

15

4

1.88

0.134–26.320

1

11

9

0.61

0.047–7.882

1

4

12

NA

NA

1

1 week

2

1

2

1

0

2

Exposed time (weeks)

 ≤ 12

5

2

0.63

0.079–4.959

1

2

5

0.18

0.026–1.279

0.169

0

4

NA

NA

0.524

 > 12

12

3

11

5

4

10

Total dose (mg)

 ≤ 3000

2

3

NA

NA

0.061

1

4

0.13

0.008–1.998

0.242

0

2

NA

NA

1

 > 3000

6

0

4

2

1

5

Chemotherapy

Yes

5

1

1.67

0.147–18.874

1

3

3

0.7

0.108–4.538

1

0

4

NA

NA

0.524

No

12

4

10

7

4

10

Endocrine therapy

Yes

2

0

NA

NA

1

3

0

NA

NA

0.526

2

1

13

0.771–219.107

0.108

No

15

5

12

8

2

13

  1. 1st trim. the first trimester, NA not applicable